{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T10:44:30Z","timestamp":1792320270837,"version":"4.4.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council (CN)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40261-016-0389-8","type":"journal-article","created":{"date-parts":[[2016,3,18]],"date-time":"2016-03-18T16:23:27Z","timestamp":1458318207000},"page":"433-441","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review"],"prefix":"10.1007","volume":"36","author":[{"given":"Xia","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fupeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"389_CR1","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"LL Baggio","year":"2007","unstructured":"Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131\u201357.","journal-title":"Gastroenterology"},{"key":"389_CR2","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/ajhp\/62.2.173","volume":"62","author":"OG Kolterman","year":"2005","unstructured":"Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62:173\u201381.","journal-title":"Am J Health Syst Pharm"},{"key":"389_CR3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.regpep.2003.10.028","volume":"117","author":"LL Nielsen","year":"2004","unstructured":"Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept. 2004;117:77\u201388.","journal-title":"Regul Pept"},{"key":"389_CR4","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","volume":"87","author":"JJ Holst","year":"2007","unstructured":"Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409\u201339.","journal-title":"Physiol Rev"},{"key":"389_CR5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.molmed.2008.01.003","volume":"14","author":"JJ Holst","year":"2008","unstructured":"Holst JJ, Deacon CF, Vilsboll T, et al. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14:161\u20138.","journal-title":"Trends Mol Med"},{"issue":"Suppl 2","key":"389_CR6","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.2337\/dc09-S315","volume":"32","author":"MA Nauck","year":"2009","unstructured":"Nauck MA, Vilsboll T, Gallwitz B, et al. Incretin-based therapies: viewpoints on the way to consensus. Diabetes Care. 2009;32(Suppl 2):S223\u201331.","journal-title":"Diabetes Care"},{"issue":"9645","key":"389_CR7","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","volume":"372","author":"DJ Drucker","year":"2008","unstructured":"Drucker DJ, Buse JB, Taylor Kendall DM, et al. Duration-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, openlabel, non-inferiority study. Lancet. 2008;372(9645):1240\u201350. doi: 10.1016\/S0140-6736(08)61206-4 .","journal-title":"Lancet"},{"issue":"9683","key":"389_CR8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39\u201347. doi: 10.1016\/S0140-6736(09)60659-0 .","journal-title":"Lancet"},{"key":"389_CR9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/1753-0407.12200","volume":"7","author":"FP Liu","year":"2015","unstructured":"Liu FP, Dong JJ, Yang Q, et al. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: a systematic review and meta-analysis. J Diabetes. 2015;7:322\u20138.","journal-title":"J Diabetes"},{"issue":"5 Pt 1","key":"389_CR10","first-page":"E981","volume":"273","author":"MA Nauck","year":"1997","unstructured":"Nauck MA, Niedereichholz U, Ettler R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 Pt 1):E981\u20138.","journal-title":"Am J Physiol"},{"key":"389_CR11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","volume":"36","author":"MA Nauck","year":"1993","unstructured":"Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741\u20134.","journal-title":"Diabetologia"},{"key":"389_CR12","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jcem.87.3.8355","volume":"87","author":"MA Nauck","year":"2002","unstructured":"Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, an insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87:1239\u201346.","journal-title":"J Clin Endocrinol Metab"},{"key":"389_CR13","unstructured":"Bydureon package insert. http:\/\/www.azpicentral.com\/bydureon\/pi_bydureon.pdf#page=1 . Accessed 23 Apr 2015."},{"key":"389_CR14","unstructured":"Tanzeum package insert. https:\/\/gsksource.com\/pharma\/content\/dam\/GlaxoSmithKline\/US\/en\/Prescribing_Information\/Tanzeum\/pdf\/TANZEUM-PI-MG-IFU-COMBINED.PDF . Accessed 3 May 2015."},{"key":"389_CR15","unstructured":"Trulicity package insert. http:\/\/pi.lilly.com\/us\/trulicity-uspi.pdf . Accessed 3 May 2015."},{"key":"389_CR16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539\u201358.","journal-title":"Stat Med"},{"key":"389_CR17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","volume":"56","author":"S Duval","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455\u201363.","journal-title":"Biometrics"},{"key":"389_CR18","unstructured":"GlaxoSmithKline. Safety and efficacy study of albiglutide in type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00849017?term=NCT00849017&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR19","unstructured":"GlaxoSmithKline. A study of the efficacy and safety of albiglutide in subjects with type 2 diabetes with renal impairment. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01098539?term=01098539&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR20","unstructured":"GlaxoSmithKline. A monotherapy study to evaluate the efficacy and safety of 2 dose levels of albiglutide in Japanese subjects with type 2 diabetes mellitus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01733758?term=01733758&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR21","unstructured":"GlaxoSmithKline. A study to determine the efficacy and safety of albiglutide as compared with liraglutide. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01128894?term=01128894&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR22","unstructured":"GlaxoSmithKline. A study to determine the safety and efficacy of albiglutide in patients with type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00838916?term=00838916&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR23","unstructured":"GlaxoSmithKline. A study to determine the safety and efficacy of albiglutide in subjects with type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00839527?term=00839527&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR24","unstructured":"GlaxoSmithKline. Efficacy and safety of albiglutide in treatment of type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00838903?term=00838903&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR25","unstructured":"GlaxoSmithKline. A study to determine the safety and efficacy of albiglutide administered in combination with insulin glargine. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00976391?term=00976391&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR26","unstructured":"GlaxoSmithKline. Safety and efficacy of albiglutide in type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00849056?term=00849056&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR27","unstructured":"AstraZeneca. Effects of exenatide long-acting release on glucose control and safety in subjects with type 2 diabetes mellitus (DURATION-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00308139?term=00308139&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR28","unstructured":"AstraZeneca. Comparison study of the glycemic effects, safety, and tolerability of exenatide once weekly suspension to sitagliptin and placebo in subjects with type 2 diabetes mellitus (DURATION-NEO-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01652729?term=NCT01652729&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR29","unstructured":"AstraZeneca. Safety and efficacy of exenatide once weekly injection versus metformin, dipeptidyl peptidase-4 inhibitor, or thiazolidinedione as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00676338?term=00676338&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR30","unstructured":"AstraZeneca. Safety and efficacy of exenatide once weekly versus liraglutide in subjects with type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01029886?term=01029886&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR31","unstructured":"AstraZeneca. Efficacy of once-weekly exenatide versus once or twice daily insulin detemir in patients with type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01003184?term=01003184&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR32","unstructured":"AstraZeneca. A study to compare the glycemic effects, safety, and tolerability of exenatide once weekly to those of sitagliptin and pioglitazone,in subjects with type 2 diabetes treated with metformin (DURATION-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00637273?term=00637273&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR33","unstructured":"Eli Lilly and Company. A study comparing the effect of dulaglutide with liraglutide in type 2 diabetes (AWARD-6). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01624259?term=01624259&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR34","unstructured":"Eli Lilly and Company. A study of dulaglutide in Japanese participants with type 2 diabetes mellitus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01584232?term=01584232&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR35","unstructured":"Eli Lilly and Company. A study of LY2189265 compared to sitagliptin in participants with type 2 diabetes mellitus on metformin. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00734474?term=00734474&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR36","unstructured":"Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (AWARD-2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01075282?term=01075282&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR37","unstructured":"Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (AWARD-4). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01191268?term=01191268&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR38","unstructured":"Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (AWARD-3). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01126580?term=01126580&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR39","unstructured":"Eli Lilly and Company. A study of LY2189265 in Japanese participants with type 2 diabetes mellitus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01558271?term=01558271&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR40","unstructured":"Eli Lilly and Company. A study of the effect of LY2189265 on blood pressure and heart rate in type 2 diabetes. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01149421?term=01149421&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR41","unstructured":"Eli Lilly and Company. A study of dose titration of LY2189265 in overweight participants with type 2 diabetes mellitus (EGO). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00630825?term=00630825&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR42","unstructured":"Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (AWARD-1). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01064687?term=01064687&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR43","unstructured":"Eli Lilly and Company. A study comparing the effects and safety of dulaglutide with insulin glargine in type 2 diabetes mellitus. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01648582?term=NCT01648582&rank=1 . Accessed 25 Oct 2015."},{"key":"389_CR44","unstructured":"U.S. Department of Food and Drug Administration. Adverse Event Reporting System [Internet], 2011. http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Surveillance\/AdverseDrugEffects\/default.htm . Accessed 31 Mar 2014."},{"key":"389_CR45","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1053\/j.gastro.2011.02.018","volume":"141","author":"M Elashoff","year":"2011","unstructured":"Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150\u20136.","journal-title":"Gastroenterology"},{"key":"389_CR46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00125-009-1591-5","volume":"53","author":"PC Butler","year":"2010","unstructured":"Butler PC, Matveyenko AV, Dry S, et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia. 2010;53:1\u20136.","journal-title":"Diabetologia"},{"key":"389_CR47","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2337\/db11-1109","volume":"61","author":"B Gier","year":"2012","unstructured":"Gier B, Matveyenko AV, Kirakossian D, et al. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D)mouse model. Diabetes. 2012;61:1250\u201362.","journal-title":"Diabetes"},{"key":"389_CR48","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"L Bjerre Knudsen","year":"2010","unstructured":"Bjerre Knudsen L, Madsen LW, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473\u201386.","journal-title":"Endocrinology"},{"issue":"11","key":"389_CR49","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.2337\/db13-1169","volume":"63","author":"T Nomiyama","year":"2014","unstructured":"Nomiyama T, Kawanami T, Irie S, et al. Exendin-4, a GLP-1 receptor agonist, attenuates prostate cancer growth. Diabetes. 2014;63(11):3891\u2013905.","journal-title":"Diabetes"},{"issue":"9","key":"389_CR50","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1210\/en.2011-1201","volume":"152","author":"JA Koehler","year":"2011","unstructured":"Koehler JA, Kain T, Drucker DJ. Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology. 2011;152(9):3362\u201372.","journal-title":"Endocrinology"},{"key":"389_CR51","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s10549-011-1585-0","volume":"132","author":"H Ligumsky","year":"2012","unstructured":"Ligumsky H, Wolf I, Israeli S, et al. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells. Breast Cancer Res Treat. 2012;132:449\u201361.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0389-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0389-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0389-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T14:29:02Z","timestamp":1567693742000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0389-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["389"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0389-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}